Theratechnologies Announces Risk of Temporary Supply Disruption for EGRIFTA SV in Early 2025 Page 1

MONTREAL, Sept. 17, 2024 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that there is a risk of temporary disruption to the supply of EGRIFTA SV (tesamorelin for injection) in early 2025, caused by an unexpected voluntary closure of the company’s contract manufacturer’s manufacturing facility following an inspection by the U.S. Food and Drug Administration (FDA), as well as the FDA’s review timeline to resume distribution of the product.

“We are working closely with our manufacturer and other stakeholders and will continue to work with the FDA to ensure production of EGRIFTA SV“, said Paul Lévesque, President and CEO of Theratechnologies. “We are confident that we will have zero impact on patients by 2025.”